Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
6.19
-0.48 (-7.20%)
At close: Apr 8, 2026, 4:00 PM EDT
6.20
+0.01 (0.16%)
Pre-market: Apr 9, 2026, 8:30 AM EDT
Artiva Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
104
Market Cap
153.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 251.00K | -33.24M | -99.25% |
| Dec 31, 2023 | 33.49M | 28.56M | 579.21% |
| Dec 31, 2022 | 4.93M | 2.93M | 146.30% |
| Dec 31, 2021 | 2.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 154.90M |
| Agenus | 114.20M |
| Spero Therapeutics | 66.80M |
| Precision BioSciences | 34.26M |
| Whitehawk Therapeutics | 7.15M |
| Molecular Partners AG | 856.30K |
| Connect Biopharma Holdings | 64.00K |
ARTV News
- 1 day ago - Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 6 weeks ago - Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 6 weeks ago - Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant - GlobeNewsWire
- 7 weeks ago - Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors - GlobeNewsWire
- 2 months ago - Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL - GlobeNewsWire
- 5 months ago - Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease - GlobeNewsWire
- 5 months ago - Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire